Mydecine Innovations Group Inc (OTC:MYCOF, NEO:MYCO) CEO Joshua Bartch tells Proactive it has appointed Dr Victoria Hale to the company’s board of directors. Bartch says Dr Hale currently serves as chair of the board of the Multidisciplinary Association for Psychedelic Studies, a non-profit research and educational organization leading the psychedelics sector in new medicine development.
What's more, the group has submitted a pre-Investigational New Drug briefing package to the FDA for a clinical study evaluating MYCO-001 in a structured smoking cessation treatment program.